Loading
Life sciences · Journal article
International Journal of Advanced Research in Science Communication and Technology · August 18, 2026
A consensus or society position rather than new primary data.
This is a narrative literature review recommending Ayurvedic Rasayana therapy as a supportive adjunct in oncology for immunomodulation and quality-of-life improvement. The source explicitly acknowledges that large-scale randomized controlled trials and standardized protocols are required before routine integration into mainstream practice, and does not report quantitative efficacy outcomes.
Narrative literature review. Published literature on Rasayana herbs in cancer care; no original study population.. Intervention: Ayurvedic Rasayana therapy (specifically Ashwagandha, Guduchi, Amalaki, Shatavari, Yashtimadhu) as adjunct to modern oncology.
Rasayana therapy is proposed as a safe supportive adjunct for enhancing immunity and reducing chemotherapy-induced toxicity Five Rasayana herbs (Ashwagandha, Guduchi, Amalaki, Shatavari, Yashtimadhu) were identified for review across immunomodulation and quality-of-life domains Authors conclude large-scale RCTs and standardized protocols are required for mainstream oncology integration
Rasayana therapy is proposed as a safe supportive adjunct for enhancing immunity and reducing chemotherapy-induced toxicity
This review presents Rasayana therapy as a potential supportive measure but does not provide quantitative evidence of efficacy or safety. Clinicians should note the explicit caveat that evidence is insufficient for routine integration without further rigorous trial data.
A literature review synthesizing classical texts and empirical studies to recommend Ayurvedic Rasayana therapy as a supportive adjunct in oncology, without reporting original trial data or hard clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This review presents Rasayana therapy as a potential supportive measure but does not provide quantitative evidence of efficacy or safety. Clinicians should note the explicit caveat that evidence is insufficient for routine integration without further rigorous trial data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective: To review the role of Ayurvedic Rasayana therapy as an adjunct to modern oncology and to evaluate its supportive, preventive, and palliative applications in cancer care. Data Source: Classical Ayurvedic texts including Charaka Samhita, Sushruta Samhita, and Ashtanga Hridaya, along with electronic databases such as PubMed, Scopus, Google Scholar, AYUSH portals, and reports from CCRAS and NIA were reviewed. Review Methods: A comprehensive literature review of publications from 2000 to 2025 was conducted, including clinical trials, observational studies, case series, and review articles. Studies evaluating Rasayana herbs such as Ashwagandha, Guduchi, Amalaki, Shatavari, and Yashtimadhu for immunomodulation, reduction of chemotherapy-induced side effects, and quality-of-life improvement were analyzed. Conclusion: Ayurvedic Rasayana therapy demonstrates promising potential as a safe and supportive adjunct in cancer management by enhancing immunity, reducing treatment-related toxicity, and improving overall quality of life. However, large-scale randomized controlled trials and standardized treatment protocols are required for its routine integration into mainstream oncology practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.